The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

Deadlines:

  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • Application Due Dates: Dec. 15, 2021; Dec. 15, 2022; Dec. 15, 2023

PAR-21-348 Expiration Date December 16, 2023

Eligibility

Faculty

Category

Medical
Medical - Basic Science
Medical - Clinical Science

External Deadline

December 15, 2022